GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) is a 335-amino acid tetrameric enzyme (~37 kDa per subunit) encoded by the GAPDH gene on chromosome 12p13.31[1]. While classically known as a glycolytic housekeeping enzyme, GAPDH has been extensively characterized as a moonlighting protein with critical non-glycolytic functions in neurodegeneration, including nuclear translocation–mediated apoptosis, oxidative stress sensing, and direct interactions with disease-associated proteins such as amyloid-beta, huntingtin, and alpha-synuclein[2]. Its dual identity as both an essential metabolic enzyme and a pro-death signal transducer makes it a nexus for understanding how energy metabolism and cell death intersect in neurodegenerative disease.
| GAPDH | |
|---|---|
| Protein Name | Glyceraldehyde-3-Phosphate Dehydrogenase |
| Gene | [GAPDH](/genes/gapdh) |
| UniProt ID | [P04406](https://www.uniprot.org/uniprot/P04406) |
| PDB ID | [1ZNQ](https://www.rcsb.org/structure/1ZNQ), [4WNC](https://www.rcsb.org/structure/4WNC) |
| Molecular Weight | ~37 kDa (monomer); ~148 kDa (tetramer) |
| Subcellular Location | Cytoplasm; nucleus (under stress) |
| Protein Family | GAPDH family (oxidoreductases) |
GAPDH functions as a homotetramer, with each 335-residue subunit organized into two domains[1:1]:
The active-site Cys152 is exceptionally reactive due to its low pKa (~5.5), which enables both glycolytic catalysis and redox sensing. S-nitrosylation of Cys152 by nitric oxide (NO) abolishes enzymatic activity and triggers the GAPDH–Siah1 nuclear translocation cascade that is central to GAPDH's pro-apoptotic role[3].
GAPDH catalyzes the reversible oxidative phosphorylation of G3P to 1,3-bisphosphoglycerate (1,3-BPG), coupling substrate oxidation to NAD+ reduction. This sixth step of glycolysis is the only energy-conserving oxidation in the pathway and generates both NADH and a high-energy acyl-phosphate bond. In neurons, which derive approximately 90% of their ATP from oxidative phosphorylation, GAPDH-generated NADH feeds the malate–aspartate shuttle to sustain mitochondrial electron transport[1:2].
GAPDH moonlights in at least six additional cellular processes[2:1]:
The most direct pro-apoptotic function of GAPDH in neurodegeneration involves its interaction with the E3 ubiquitin ligase Siah1 (Seven in Absentia Homolog 1)[3:1]. Under conditions of oxidative or nitrosative stress:
This cascade has been demonstrated in cell models of Huntington's disease (polyQ-expanded huntingtin induces GAPDH nuclear accumulation), Parkinson's disease (MPTP/MPP+ drives GAPDH S-nitrosylation via nNOS), and Alzheimer's disease (Abeta oligomers increase GAPDH nuclear translocation in hippocampal neurons)[4][5].
Because the active-site Cys152 is extremely sensitive to reactive oxygen species (ROS), GAPDH is among the first glycolytic enzymes inactivated during oxidative stress. In AD, PD, and ALS, post-mortem studies show 30–50% reductions in GAPDH activity in affected brain regions, correlating with lactate accumulation and energy crisis[8]. Paradoxically, transient GAPDH inactivation diverts glycolytic flux through the pentose phosphate pathway, generating NADPH to combat oxidative damage — a protective metabolic switch that may be overwhelmed in chronic neurodegeneration.
Under severe oxidative stress, GAPDH forms high-molecular-weight aggregates with amyloid-like cross-beta structure. These aggregates are cytotoxic and have been identified in post-mortem AD cortex, where they colocalize with neurofibrillary tangles. GAPDH aggregation is accelerated by the same conditions — elevated NO, ROS, and metal ions — that drive disease protein misfolding[9].
The MAO-B inhibitors selegiline (deprenyl) and rasagiline were found to exert anti-apoptotic effects partly by blocking GAPDH–Siah1 binding and nuclear translocation, independent of their monoamine oxidase inhibition[3:2]. This "GAPDH-stabilizing" activity is thought to contribute to the neuroprotective signal observed in the DATATOP and ADAGIO trials in PD.
CGP3466B is a deprenyl derivative specifically designed to block GAPDH nuclear translocation without MAO inhibitory activity. It showed neuroprotection in MPTP and SOD1-G93A mouse models but failed to reach efficacy endpoints in a Phase II/III ALS trial, possibly due to advanced disease stage at enrollment[10].
Structure-activity studies identified the propargylamino pharmacophore as the critical moiety for disrupting the GAPDH–Siah1 interface. Several next-generation propargylamines (TCH346, ladostigil) retain GAPDH-stabilizing activity while adding additional mechanisms (cholinesterase inhibition, iron chelation) relevant to AD and PD.
Sirover MA. On the functional diversity of glyceraldehyde-3-phosphate dehydrogenase: biochemical mechanisms and regulatory control. Biochim Biophys Acta. 2011. ↩︎ ↩︎ ↩︎
Sirover MA. Moonlighting glyceraldehyde-3-phosphate dehydrogenase: posttranslational modification, protein and nucleic acid interactions in normal cells and in human pathology. Crit Rev Biochem Mol Biol. 2020. ↩︎ ↩︎
Hara MR, Agrawal N, Kim SF, et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol. 2005. ↩︎ ↩︎ ↩︎
Burke JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med. 1996. ↩︎ ↩︎
Mazzola JL, et al. Amyloid-beta peptide induces glyceraldehyde-3-phosphate dehydrogenase conformational changes and cell death. J Alzheimers Dis. 2006. ↩︎ ↩︎
Tsuchiya K, Tajima H, Kuwae T, et al. Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions. Eur J Neurosci. 2005. ↩︎
Butterfield DA, Hardas SS, Lange ML. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease. J Alzheimers Dis. 2010. ↩︎
Mazzola JL, et al. Reduced glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer disease brain. Neurosci Lett. 2001. ↩︎
Nakajima H, Amano W, Kubo T, et al. Glyceraldehyde-3-phosphate dehydrogenase aggregate formation participates in oxidative stress-induced cell death. J Biol Chem. 2009. ↩︎
Miller RG, et al. CGP 3466B (omigapil) in amyotrophic lateral sclerosis: results of a multicenter trial. Neurology. 2006. ↩︎